A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms

Talleur, Aimee C

doi:10.1016/j.xcrm.2023.100949

Cited by 2 publications

(2 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the excessive cost and high price of CAR-T products and the poor financial capacity of most patients can be another obstacles in the clinic. The resistance to CAR-T therapy is also one of the issues that continues to be addressed [263][264][265]. Regarding therapeutic targets, currently, CAR-T therapy only is effective in treating B cell-derived cancer, such as B-ALL, B cell lymphoma and myeloma.…”

Section: Enhancing Car-t Therapy Through Nanotechnologymentioning

confidence: 99%

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

Wang

Han

et al. 2023

J Hematol Oncol

View full text Add to dashboard Cite

Hematologic malignancies (HMs) pose a serious threat to patients’ health and life, and the five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis and the complex clinical symptoms brings immense challenges to the diagnosis and treatment of HMs. Traditional therapeutic strategies for HMs include radiotherapy, chemotherapy, targeted therapy and hematopoietic stem cell transplantation. Although immunotherapy and cell therapy have made considerable progress in the last decade, nearly half of patients still relapse or suffer from drug resistance. Recently, studies have emerged that nanomaterials, nanotechnology and nanomedicine show great promise in cancer therapy by enhancing drug targeting, reducing toxicity and side effects and boosting the immune response to promote durable immunological memory. In this review, we summarized the strategies of recently developed nanomaterials, nanotechnology and nanomedicines against HMs and then proposed emerging strategies for the future designment of nanomedicines to treat HMs based on urgent clinical needs and technological progress.

show abstract

Section: Enhancing Car-t Therapy Through Nanotechnologymentioning

confidence: 99%

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

Wang

Han

et al. 2023

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…The mechanisms of resistance to CAR-T cells are most likely due to multiple factors, that may involve both the target lymphoma cells as well as the immune effector cells of the host. In more detail, the resistance mechanisms characterized to date include alterations of the tumor microenvironment, the loss of the expression of the CD19 antigen on the lymphoma cell surface, the properties and functionality of the CAR19 T cells themselves, as well as the function and potential exhaustion of the immune system of the host ( 12 ). Despite a certain advancement in the field, at present the resistance mechanisms to CAR19 T cells are far from being fully understood.…”

mentioning

confidence: 99%

A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance

Mouhssine,

Maher,

Gaidano

2023

Transl Cancer Res

View full text Add to dashboard Cite

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms

Cited by 2 publications

References 7 publications

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance

Contact Info

Product

Resources

About